Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 12/20 | 0.52 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.52 |
| ▸ | GPR174 | Q9BXC1 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968303 | 1.00 | P2RY10 (0.52) | P2RY10GPR34GPR174 | |
| SCHEMBL9957361 | 0.93 | PLA2G2C (0.52) | P2RY10GPR34GPR174 | |
| SCHEMBL18315980 | 0.93 | PLA2G2C (0.52) | P2RY10GPR34GPR174 | |
| SCHEMBL16571348 | 0.82 | P2RY10 (0.44) | P2RY10GPR34 | |
| SCHEMBL969822 | 0.80 | P2RY10 (0.44) | P2RY10GPR34GPR174 | |
| SCHEMBL18262003 | 0.80 | P2RY10 (0.44) | P2RY10GPR34GPR174 | |
| SCHEMBL7571747 | 0.80 | P2RY10 (0.44) | P2RY10GPR34GPR174 | |
| SCHEMBL25354353 | 0.80 | P2RY10 (0.76) | P2RY10GPR34GPR174 | |
| SCHEMBL274999 | 0.80 | P2RY10 (0.76) | P2RY10GPR34GPR174 | |
| SCHEMBL22493901 | 0.80 | P2RY10 (0.76) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8398967-B2 | Particle formulations for use in pharmaceutical compositions | INTARCIA THERAPEUTICS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8257691-B2 | Composition and dosage form comprising a particle formulation and suspending vehicle | INTARCIA THERAPEUTICS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110208168-A1 | PARTICLE FORMULATIONS FOR USE IN PHARMACEUTICAL COMPOSITIONS | INTARCIA THERAPEUTICS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110195097-A1 | COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE | INTARCIA THERAPEUTICS, INC. | 2011-08-11 | — | — | US | disclosed |
| US-7964183-B2 | Composition and dosage form comprising a particle formulation and suspending vehicle | INTARCIA THERAPEUTICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7731947-B2 | Composition and dosage form comprising an interferon particle formulation and suspending vehicle | INTARCIA THERAPEUTICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100112070-A1 | Composition and dosage form comprising a particle formulation and suspending vehicle | INTARCIA THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| EP-2116230-A2 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | Intarcia Therapeutics, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20050112188-A1 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | INTARCIA THERAPEUTICS, INC. | 2005-05-26 | — | — | US | disclosed |
| EP-0975331-A1 | A NOVEL BIOADHESIVE DRUG DELIVERY SYSTEM BASED ON LIQUID CRYSTALS | DUMEX-ALPHARMA A/S (DK) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047487-A1 | A NOVEL BIOADHESIVE DRUG DELIVERY SYSTEM BASED ON LIQUID CRYSTALS | DUMEX-ALPHARMA A/S (DK) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112070-A1 | Composition and dosage form comprising a particle formulation and suspending vehicle | ABCB11, SLC47A1, AQP1 | P2RY10 3552/4885GPR34 1690/4885GPR174 1345/4885 |
| US-20110195097-A1 | COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE | ABCB11, SLC47A1, AQP1 | P2RY10 3552/4885GPR34 1690/4885GPR174 1345/4885 |
| US-20050112188-A1 | Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle | ANXA6, SLC47A2, SLC47A1 | P2RY10 4236/4885GPR34 1766/4885GPR174 1332/4885 |
| US-20110208168-A1 | PARTICLE FORMULATIONS FOR USE IN PHARMACEUTICAL COMPOSITIONS | AQP1, AQP3, ABCB11 | P2RY10 2151/4885GPR34 2330/4885GPR174 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.